Emergent BioSolutions (EBS) Stock Analysis & AI Equity Report
Emergent BioSolutions (EBS) overview
Emergent BioSolutions (EBS) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 743m and operating profit of USD 100m; the year-end share price was 12.36 USD and market capitalisation was USD 644m. Emergent BioSolutions is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Emergent BioSolutions's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Emergent BioSolutions
Emergent BioSolutions develops and supplies products and services addressing public health threats, including chemical, biological, radiological and nuclear threats, emerging infectious diseases, health crises, and emergency care. Its portfolio includes naloxone nasal sprays, anthrax and smallpox medical countermeasures, and contract development and manufacturing services. Customers include government agencies, pharmacies, health departments, law enforcement, and community organizations.
Generate the Emergent BioSolutions report
Emergent BioSolutions is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Emergent BioSolutions and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Emergent BioSolutions
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.